rttnews Neutral 2 months ago Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market Zacks Neutral 2 months ago Ginkgo Bioworks Holdings, Inc. (DNA) Outpaces Stock Market Gains: What You Should Know Zacks Neutral 150Results | Showing1 out of 19 News Score - Last...
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentat
Ginkgo Bioworks Holdings Inc. options data by MarketWatch. View DNA option chain data and pricing information for given maturity periods.
Ginkgo Bioworks Holdings, Inc. (纽交所:DNA) 打破分析师的预测,发布其季度业绩,超出市场预期。营业收入达到8900万美元,远超预期。 Simply Wall St2024/11/15 19:58 TD Cowen维持Ginkgo Bioworks(DNA.US)买入评级,维持目标价10美元 TD Cowen分析师Brendan Smith维持$Ginkgo Bioworks(DNA.US)$买入评级,维持目...
Headquartered in Boston, Ginkgo Bioworks uses the most advanced technology on the planet—biology—to grow better products. Our cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceutical
Ginkgo Bioworks Holdings sentiment based on opinions from InvestorPlace, SeekingAlpha and others. Sentiment for Ginkgo Bioworks Holdings is 25.95% less bearish than other Healthcare sector stocks.
Ginkgo Bioworks盘中异动 急速拉升5.00% 市场资讯01/17 01:55 TD Cowen 对 Ginkgo Bioworks Holdings (DNA) 获得买入评级 TipRanks01/14 20:57· 评级/大行评级 银杏生物科技公司与亚斯利康旗下的环球细胞公司合作,推进下一代来自iPSC的固体肿瘤细胞疗法。 此次合作利用了Ginkgo的电芯工程和筛选平台,以增强Universa...
Latest Ginkgo Bioworks Holdings Inc (9L40:BER) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
Ginkgo Bioworks Holdings Inc. Annual balance sheet by MarketWatch. View all DNA assets, cash, debt, liabilities, shareholder equity and investments.
合成生物学领先公司Ginkgo Bioworks Holdings Inc.(纽约证券交易所代码:DNA)公布了2024年第三季度财务业绩,强调了战略进展和显著的成本削减。首席执行官Jason Kelly和首席财务官Mark Dmytruk强调公司旨在实现调整后EBITDA收支平衡,同时保持6.16亿美元的强劲现金状况,且无银行债务。 尽管细胞工程收入下降20%,但Ginkgo与默沙...